Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of Its SARS-CoV-2 Vaccine Candidate

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc. announced the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study.